http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012289467-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfead37a4af7d54f8ab639fad45451d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2164408dacecef4586f14fbce057031a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf2f9d7a4750140d49d392eefe7633c5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75 |
| filingDate | 2008-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b84587cfef706aeed78e4539e979616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fffdd9b2f82801862438f032eecd282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4f5ae4859d8ecbebf2a32535597c3d8 |
| publicationDate | 2012-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2012289467-A1 |
| titleOfInvention | Compositions and Methods Utilizing Fibrin Beta Chain Fragments |
| abstract | A composition including a peptide sequence of the formula βX1-X2, the peptide sequence corresponding to an amino acid sequence of a fibrin beta chain fragment of a Bbeta chain of fibrinogen, wherein X1 represents an N-terminal end of the peptide sequence, and X2 represents a C-terminal end of the peptide sequence, wherein the peptide sequence includes additional amino acids between X1 and X2, wherein the peptide sequence may contain a non-naturally occurring amino acid residue, wherein the peptide sequence is other than a wild-type β15-42 monomer sequence per se, and wherein the peptide sequence is other than (β15-66) 2 dimer having two chains with each chain limited to wild type amino acids β15-65 and each chain further including a non-naturally occurring Gly at position 66 of each chain. Methods for treatment and pharmaceutical combinations may include a polypeptide agent such as Thymosin beta 4. In such methods and combinations, a dimer of the peptide sequence may include amino acids 15-66 of the fibrin beta chain. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110988353-A |
| priorityDate | 2007-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.